Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.94% $0.529
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 29.03 mill |
EPS: | -1.170 |
P/E: | -0.450 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 54.92 mill |
Avg Daily Volume: | 2.51 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.450 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.08x |
Company: PE -0.450 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.155 (-70.64%) $-0.373 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 0.286 - 0.772 ( +/- 45.97%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Do Cuong V | Buy | 10 000 | Common stock |
2024-03-04 | Do Cuong V | Buy | 5 000 | Warrants (right to buy) |
2023-12-11 | Kim Joanne Wendy | Buy | 5 000 | Common Stock |
2023-11-09 | Lang James Paul | Buy | 93 500 | Stock Option (right to buy) |
2023-11-09 | Gorlin Steve | Buy | 46 358 | Common Stock |
INSIDER POWER |
---|
92.55 |
Last 94 transactions |
Buy: 39 235 676 | Sell: 4 917 434 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.529 (-0.94% ) |
Volume | 0.774 mill |
Avg. Vol. | 2.51 mill |
% of Avg. Vol | 30.88 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.